title: Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity.
abstract: The human immunodeficiency virus type 1 exterior gp120 envelope glycoprotein is highly flexible, and this flexibility may contribute to the inability of monomeric gp120 immunogens to elicit broadly neutralizing antibodies. We previously showed that an S375W modification of a critical interfacial cavity central to the primary receptor binding site, the Phe43 cavity, stabilizes gp120 into the CD4-bound state. However, the immunological effects of this cavity-altering replacement were never tested. Subsequently, we screened other mutations that, along with the S375W alteration, might further stabilize the CD4-bound state. Here, we define a selected second cavity-altering replacement, T257S, and analyze the double mutations in several gp120 envelope glycoprotein contexts. The gp120 glycoproteins with the T257S-plus-S375W double mutation (T257S+S375W) have a superior antigenic profile compared to the originally identified single S375W replacement in terms of enhanced recognition by the broadly neutralizing CD4 binding-site antibody b12. Isothermal titration calorimetry measuring the entropy of the gp120 interaction with CD4 indicated that the double mutant was also stabilized into the CD4-bound state, with increasing relative fixation between core, full-length monomeric, and full-length trimeric versions of gp120. A significant increase in gp120 affinity for CD4 was also observed for the cavity-filling mutants relative to wild-type gp120. The most conformationally constrained T257S+S375W trimeric gp120 proteins were selected for immunogenicity analysis in rabbits and displayed a trend of improvement relative to their wild-type counterparts in terms of eliciting neutralizing antibodies. Together, the results suggest that conformational stabilization may improve the ability of gp120 to elicit neutralizing antibodies.
authors.affiliation: Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Barna
authors.initials: B
authors.lastname: Dey
authors.forename: Marie
authors.initials: M
authors.lastname: Pancera
authors.forename: Krisha
authors.initials: K
authors.lastname: Svehla
authors.forename: Yuuei
authors.initials: Y
authors.lastname: Shu
authors.forename: Shi-Hua
authors.initials: SH
authors.lastname: Xiang
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Vainshtein
authors.forename: Yuxing
authors.initials: Y
authors.lastname: Li
authors.forename: Joseph
authors.initials: J
authors.lastname: Sodroski
authors.forename: Peter D
authors.initials: PD
authors.lastname: Kwong
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
authors.forename: Richard
authors.initials: R
authors.lastname: Wyatt
mesh_terms: D000818:Animals; D001666:Binding Sites, Antibody; D015704:CD4 Antigens / Q000378:metabolism*; D002460:Cell Line; D005260:Female; D015699:HIV Envelope Protein gp120 / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D015497:HIV-1 / Q000737:chemistry* / Q000276:immunology / Q000378:metabolism*; D006801:Humans; D009500:Neutralization Tests; D011485:Protein Binding / Q000276:immunology; D011487:Protein Conformation; D011817:Rabbits; D013816:Thermodynamics
chemical_list: D015704:CD4 Antigens; D015699:HIV Envelope Protein gp120